The US Generic Drug Market
The largest alleged price-fixing cartel in US history
Generic drugs account for the large majority of US prescriptions and are supposed to keep costs low through competition. Yet since 2016, federal prosecutors and a coalition of more than 40 state attorneys general have alleged that generic manufacturers colluded to raise prices on hundreds of medicines. The result has been criminal charges, deferred prosecution agreements with multiple companies, and state settlements running to hundreds of millions of dollars, with the first state trial expected in late 2026.
Questions
What is the generic drug price-fixing scandal?
Federal criminal cases and state civil suits allege that manufacturers agreed to divide customers and coordinate price increases on 100+ common medicines — Teva is the lead defendant — with some increases exceeding 1,000%.
It is a set of federal criminal cases and state civil lawsuits alleging that generic manufacturers agreed not to compete, dividing up customers and coordinating price increases on common medicines. The state case, led by Connecticut, alleges a conspiracy involving more than 100 generic drugs, 20 corporate defendants and 15 individual executives, with Teva as the lead defendant, and price increases in some instances exceeding 1,000%. The states have filed three separate complaints; the first named Heritage and 17 other corporate defendants covering 15 drugs. The federal Justice Department prosecuted the conduct as criminal Sherman Act violations. Because generics are the drugs most Americans take, the alleged cartel affected a very wide range of patients and payers.
Q2How did the alleged conspiracy work?
Executives met at industry dinners, golf outings and 'girls nights out' using coded terms like 'fair share' and 'playing nice in the sandbox' to allocate customers — ceding prescriptions to new entrants rather than competing on price and following each other's increases.
According to the states, competitors used social relationships to coordinate. Executives allegedly met at industry dinners, "girls nights out," lunches, cocktail parties and golf outings and communicated by phone, email and text. The complaint alleges they used terms such as "fair share," "playing nice in the sandbox" and "responsible competitor" to describe an understanding that each company would get its allocated share of a market and would not undercut rivals. When a new competitor entered, incumbents would allegedly cede some customers rather than compete on price, and companies would follow each other's price increases. The states describe this as an "ingrained culture of collusion." Defendants that have not settled deny the allegations, and the civil claims have yet to be tested at trial.
Q3What criminal charges were brought?
The DOJ prosecuted seven generic companies — Sandoz paid $195M, Teva $225M under a 2023 deferred prosecution, Glenmark $30M — with consumers likely overcharged by at least $350 million on the conspiracies charged against Teva alone.
The Justice Department's Antitrust Division pursued criminal prosecutions against seven generic pharmaceutical companies accused of conspiring to fix prices, rig bids and allocate markets. In March 2020 Sandoz, then part of Novartis, agreed to a $195 million criminal penalty. Teva was indicted in August 2020 and, after three years of litigation, entered a deferred prosecution agreement in August 2023 with a $225 million penalty, admitting conspiracies involving pravastatin, clotrimazole and tobramycin. Glenmark paid $30 million over pravastatin, and the DOJ had alleged Glenmark and others raked in $200 million from the pravastatin scheme alone. Teva was also accused of conspiring with Taro and with Sandoz on other drugs. The Justice Department described consumers as likely overcharged by at least $350 million in the conspiracies charged against Teva.
Q4What was unusual about the Teva and Glenmark resolutions?
Both were required to divest their pravastatin businesses — a 'novel' criminal antitrust remedy — and Teva's deferred prosecution agreement, reached after three years of litigation, appears unprecedented for the Antitrust Division, allowing it to avoid mandatory federal healthcare exclusion.
Two things. First, the Justice Department required both companies to divest their pravastatin businesses, a remedy it called "extraordinary" and which commentators described as novel in a criminal antitrust case. The goal was to restore competition in the market for the cholesterol drug at the centre of the conspiracy. Second, the agreements were deferred prosecution agreements reached after three years of litigation rather than at the time of charging, which appears to be unprecedented for the Antitrust Division. Deferred prosecution allowed Teva to avoid a conviction that would have triggered mandatory exclusion from federal healthcare programmes, which would have been devastating for the largest US generic supplier. Teva also agreed to donate $50 million of generic drugs.
Q5What have state attorneys general recovered so far?
Sandoz agreed in principle to ~$469 million in August 2026 (the largest settlement); Apotex and Heritage paid $49.1 million combined; Lannett and Bausch $17.85 million — with Teva, the lead defendant, still unsettled in the state civil case.
The states have reached several settlements. Apotex and Heritage settled for $49.1 million combined, and Lannett and Bausch Health for $17.85 million. Two former Heritage executives, Jeffery Glazer and Jason Malek, settled and are cooperating. The largest settlement came in August 2026, when Sandoz agreed in principle to pay approximately $469 million to state attorneys general, including amounts under earlier settlements with some states, and to implement significant antitrust compliance reforms. Oklahoma's attorney general said companies that illegally inflate prices "are taking money directly out of the pockets" of residents. Settlements have typically included compliance reforms as well as money. Teva, the lead defendant, has not settled the state civil case.
Q6What are the fraudulent transfer allegations against Novartis?
States alleged Novartis drained assets from its US Sandoz subsidiary and spun it off in 2023 to shield itself from liability — a theory the August 2026 Sandoz settlement resolved, paralleling concerns in opioid litigation about companies using corporate structures to limit exposure.
The states alleged that Novartis, Sandoz's former parent, took steps to fraudulently transfer and drain assets from Sandoz, Inc., a defendant in the state antitrust complaints, and spun Sandoz off in 2023 to shield Novartis from liability. This is significant because corporate restructurings, such as spin-offs and bankruptcies, can leave plaintiffs pursuing an entity with fewer assets than the one that allegedly profited from misconduct. The August 2026 Sandoz settlement resolves allegations against Novartis AG, Sandoz AG and Sandoz Group AG, including the fraudulent transfer claims. The use of fraudulent transfer theories in this case parallels concerns raised in opioid litigation about companies using corporate structures to limit liability, notably in Purdue Pharma's and Mallinckrodt's opioid bankruptcies.
Q7Have generic makers also faced False Claims Act liability?
Yes — Teva paid $25 million in October 2024 to resolve civil allegations that price-fixing on Medicare and Medicaid claims constituted false claims, creating a second layer of exposure beyond antitrust law and a recovery avenue for inflated government payments.
Yes. Because Medicare and Medicaid pay for many generic prescriptions, inflated prices can also give rise to False Claims Act liability. The Justice Department's Civil Division investigated whether generic manufacturers engaged in market allocation and price-fixing, paid illegal remuneration, and caused false claims to government health programmes. In October 2024 Teva agreed to pay $25 million to resolve those civil allegations, without admitting wrongdoing, alongside its separate $425 million Copaxone settlement. The theory is that the benefits a company receives under a price-fixing scheme can amount to illegal kickbacks, and claims for drugs sold at conspiracy prices are tainted. This creates a second layer of exposure beyond antitrust law, and it means federal programmes can seek recovery for inflated payments.
Q8How does generic price-fixing harm patients?
Drugs named in Teva's indictment include pravastatin, warfarin, carbamazepine and tobramycin — old essentials that become very cheap under real competition — with uninsured patients paying increases directly and shortages arising when companies exit unprofitable markets.
Generics usually become very cheap when multiple manufacturers compete. When they allegedly coordinate instead, the price of old, essential medicines can rise sharply. The drugs named in Teva's indictment include widely used medicines such as pravastatin (cholesterol), warfarin (blood thinner), carbamazepine (seizures), clotrimazole (fungal infections) and tobramycin (eye infections). The DOJ also cited collusion on drugs for brain cancer, cystic fibrosis and hypertension, and on drugs for arthritis and seizures with Taro. Uninsured patients and those paying coinsurance feel increases directly, and government programmes and employers pay more. Price spikes on generics can also contribute to shortages when companies exit unprofitable markets. The alleged cartel therefore matters not only for its dollar value but for its effect on access to basic medicines.
Q9How did the generic price-fixing investigation begin?
Connecticut's AG opened the investigation in 2015–16 after receiving subpoenas from Actavis and Teva; 49 states filed a civil action on December 15, 2016; a broader 44-state complaint naming 20 manufacturers followed in 2019 — with cooperation from two former Heritage executives providing key evidence.
The state investigation started in Connecticut. According to Teva's securities filings, in 2015 and 2016 Actavis and Teva USA received subpoenas from the Connecticut Attorney General seeking information on potential state antitrust violations. On December 15, 2016, attorneys general of 49 states, the District of Columbia and Puerto Rico filed a civil action, later amended, that included claims against both companies. In May 2019 a coalition of 44 states filed a much broader second complaint naming Teva and 19 other manufacturers and 15 individuals; it was unsealed in June 2019. A third complaint followed. In parallel, the Justice Department opened criminal and civil investigations, with Teva receiving a civil investigative demand in May 2018. The cooperation of former Heritage executives has been an important source of evidence for the states.
Q10How much money has been paid so far?
Known resolutions exceed $1 billion: Sandoz $195M criminal + $469M state; Teva $225M criminal + $25M False Claims Act; Glenmark $30M; Apotex and Heritage $49.1M; Lannett and Bausch $17.85M — with Teva still unsettled in the state civil case.
The known resolutions add up to well over $1 billion. On the criminal side, Sandoz paid a $195 million penalty, Teva $225 million and Glenmark $30 million; these were among seven generic companies prosecuted by the Antitrust Division. Teva also paid $25 million to resolve related civil False Claims Act allegations. On the state side, Sandoz agreed to about $469 million, Apotex and Heritage paid a combined $49.1 million, and Lannett and Bausch $17.85 million. According to the states, the drugs involved generated billions of dollars in US sales, so the eventual total, including any recovery from Teva, could be considerably larger. Several settlements also require compliance reforms.
Q11What is Teva's position in the generic price-fixing cases?
Teva admitted three narrow instances of bid-rigging in 2013–15 via one former employee; it disputes the states' far broader conspiracy allegations covering 100+ drugs and senior executives — the gap between those positions is exactly what a trial would test.
Teva has taken a two-track approach. In the criminal case it admitted limited conduct: three instances between 2013 and 2015 in which it agreed with competitors not to bid for a customer's business, involving pravastatin, clotrimazole and tobramycin. It attributed that conduct to a single former employee. In the civil state litigation, which alleges a far broader conspiracy involving senior executives and more than 100 drugs, Teva has not settled and disputes the allegations. It settled the related civil False Claims Act matter for $25 million without admitting wrongdoing, and said the settlements include no admission of wrongdoing. The gap between Teva's narrow admissions and the states' broad allegations is exactly what a trial would test. Because Teva is the largest US generic supplier, the outcome could have significant consequences for its finances and for how the industry operates.
Q12What should I watch for in the generic price-fixing litigation?
The first state trial in Hartford, Connecticut in late 2026 will put the states' evidence of industry-wide collusion before a jury for the first time — its outcome could decisively shape remaining settlement talks with Teva and the future of generic market competition.
The next major milestone is the first state trial, expected in Hartford, Connecticut in late 2026. That trial would put the states' evidence of industry-wide collusion before a jury for the first time and could influence remaining settlement talks, especially with Teva. The criminal phase is largely complete, although Teva's deferred prosecution agreement runs until its obligations, including a $135 million final payment in 2028, are met. Another question is whether courts accept the states' use of fraudulent transfer theories against parent companies, which the Sandoz settlement resolved without a ruling. And because many essential generics are made by only a handful of suppliers, the case has prompted wider debate about how to keep these markets competitive. With three state complaints outstanding, the first of which named Heritage and 17 other corporate defendants, the litigation is likely to continue for years.